{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 304,
  "pageCount": 415,
  "prevPage": 303,
  "nextPage": 305,
  "slideType": "villain_critique",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a 'villain_critique' structure to undermine a competitor's clinical trial results by citing an expert's negative testimony.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/304",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-304",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The investigator thoroughly trashed Vykat and the clinical trials, stating he saw no benefit in any of his enrollees; that he \"encouraged them not to continue\" into the open-label extension; that only one patient remains on drug, for a discontinuation rate of ~80%; and that he is skeptical of the mother’s perception of benefit in the one remaining patient on the drug.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b1-3a083b9919b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "Longtime, globally recognized authority on Prader-Willi with a particular focus on hyperphagia... Involved with key Soleno trials as PI, high discontinuation rate with only one patient left on drug... No benefit in approximately 5 enrollees; PI didn't want to encourage families to continue on drug; skeptical of one parent",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8623372d-a3b0-48e1-aa4c-813d1559951e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "The investigator thoroughly trashed Vykat and the clinical trials, stating he saw no benefit in any of his enrollees; that he \"encouraged them not to continue\" into the open-label extension; that only one patient remains on drug, for a discontinuation rate of ~80%; and that he is skeptical of the mother’s perception of benefit in the one remaining patient on the drug.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00522f90-9fb4-46b8-b010-7a13893566a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"I have been publishing in this area for 20 or 30 years. The first study we did in the 1980's. I've been involved in providing second opinions to many people with Prader-Willi Syndrome over the years, and have seen many as part of the research projects. Our research projects have been focused on hyperphagia. And I've been an advisor to the [Prader-Willi association name redacted] and, at the present time, [title redacted] of the [Prader-Willi organization name redacted]. Through the PWS, associations, I'm asked to speak to parents, but quite often I speak to clinicians, and we work through the issues of what might be the most appropriate medication or the most appropriate course of action in any given situation.\" — Trial investigator, key opinion leader for PWS",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b1-3d7a9df695ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a6e1859-19d0-4fad-816c-f322c55351eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Trial investigator #3: A longtime, globally recognized authority on Prader-Willi Syndrome",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36304e63-f5c7-4d20-aeb4-727f3b7003c6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "villain_critique",
      "slug": null,
      "matchId": "636d6561-1d7d-495f-a074-61b74ae084f4",
      "evidence": "Uses expert testimony to discredit competitor clinical trial efficacy and retention.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}